{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:55:05Z","timestamp":1791046505083,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Clinical Translational Science Center","award":["UL1-RR024996"],"award-info":[{"award-number":["UL1-RR024996"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.wneu.2011.05.056","type":"journal-article","created":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T07:11:11Z","timestamp":1321945871000},"page":"130-134","source":"Crossref","is-referenced-by-count":97,"title":["Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival"],"prefix":"10.1016","volume":"77","author":[{"given":"Jan-Karl","family":"Burkhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Riina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Kesavabhotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos John","family":"Tsiouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Boockvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2011.05.056_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11910-008-0035-9","article-title":"Bevacizumab in recurrent malignant glioma","volume":"8","author":"Abrey","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.wneu.2011.05.056_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3171\/2010.9.JNS101223","article-title":"Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma","volume":"114","author":"Boockvar","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.wneu.2011.05.056_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","article-title":"A perivascular niche for brain tumor stem cells","volume":"11","author":"Calabrese","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2011.05.056_bib4","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2006.08.1661","article-title":"Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials","volume":"25","author":"Carson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib5","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.4161\/cc.9.15.12710","article-title":"The perivascular niche microenvironment in brain tumor progression","volume":"9","author":"Charles","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.wneu.2011.05.056_bib6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.wneu.2011.05.056_bib7","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archneurol.2010.11","article-title":"Bevacizumab for malignant gliomas","volume":"67","author":"Iwamoto","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2011.05.056_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1215\/15228517-2007-062","article-title":"Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas","volume":"10","author":"Lamborn","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib12","first-page":"145","article-title":"Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma","volume":"8","author":"Riina","year":"2009","journal-title":"J Exp Ther Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/159101991001600109","article-title":"Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma","volume":"16","author":"Riina","year":"2010","journal-title":"Interv Neuroradiol"},{"key":"10.1016\/j.wneu.2011.05.056_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2011.05.056_bib16","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09624","article-title":"Glioblastoma stem-like cells give rise to tumour endothelium","volume":"468","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2011.05.056_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.wneu.2011.05.056_bib19","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2011.05.056_bib20","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875011006917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875011006917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T08:04:16Z","timestamp":1572768256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875011006917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1878875011006917"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2011.05.056","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}